UNSPSC 51143901: Cathine hydrochloride

This classification denotes an alkaloid with the molecular formula C9H13NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX73851J3P, chemically known as s,s-norpseudoephedrine hydrochloride but more generally known as cathine hydrochloride, which bears US NIH Compound Identifier 9065. European Medicines Agency schedules Cathine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01089MIG. Most nations, for tariff and trade purposes, schedule cathine hydrochloride under HS 29394300.

As of Q4 2014, CATHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@H](C1CCCCC1)O)N.CL.

UNSPSC 51143901 Cathine hydrochloride is a Commodity code for a controlled pharmaceutical ingredient, but recent state and local opportunities show minimal direct procurement activity under this specific code. The three recent opportunities posted between January and June 2026 focus on broader pharmaceutical and drug-management categories—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—rather than cathine hydrochloride itself. State and local issuing bodies that appear in these records include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multi-state and multi-jurisdiction networks (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and participating state and local facilities).

Geographic activity concentrates in Florida, Texas, and Minnesota, with the MMCAP cooperative extending purchasing reach across multiple states. The Seminole County, Florida IFB for naloxone and safe drug deactivation systems (IFB60459723LAS, due July 26, 2023) represents traditional county procurement; the Texas HHS Commission RFI for direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) signals state-level interest in pharmacy supply chain restructuring; and the MMCAP RFP for generic multi-source pharmaceuticals (S1070000015802, due March 26, 2026) demonstrates cooperative purchasing leverage across state and local jurisdictions. The code itself shows little relevant recent procurement activity—opportunities are tagged under broader pharmaceutical acquisition categories rather than cathine hydrochloride specifically, suggesting that state and local demand for this commodity code either does not surface as standalone line items or routes through established pharmaceutical distribution and cooperative purchasing frameworks rather than direct solicitations.